QT dispersion as a predictor of acute heart failure after high-dose cyclophosphamide.
No useful predictor of risk of acute heart failure in peripheral-blood stem-cell transplantation (PBSCT) regimens, Including high-dose cyclophosphamide, has previously been available. Corrected QT dispersion can predict acute heart failure after high-dose cyclophosphamide chemotherapy used in PBSCT.
Nakamae
H
H
Tsumura
K
K
Hino
M
M
Hayashi
T
T
Tatsumi
N
N
D000293:Adolescent; D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004562:Electrocardiography / Q000187:drug effects*; D005260:Female; D006333:Heart Failure / Q000139:chemically induced* / Q000175:diagnosis; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D008133:Long QT Syndrome / Q000139:chemically induced* / Q000175:diagnosis; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D018570:Risk Assessment
D018906:Antineoplastic Agents, Alkylating; D003520:Cyclophosphamide